SCHEMBL7244362

SCHEMBL7244362

Cn1c(CCc2ccc(C#N)cc2)nc2cc(C(=O)NCCNc3ccccc3)ccc21

nearest known ligand 0.54

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 7/20 0.54
ALDH1A1 P00352 1/20 0.48
HSD17B10 Q99714 1/20 0.48
GAA P10253 1/20 0.48
ITK Q08881 1/20 0.47
F2 P00734 1/20 0.47
NPC1 O15118 3/20 0.47
RAB9A P51151 3/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
HDAC1 Q13547 1/20 0.46
MAPT P10636 2/20 0.46
POLB P06746 1/20 0.46
TP53 P04637 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7246014 0.89 HDAC1 (0.50) HDAC6ALDH1A1HSD17B10GAAF2
SCHEMBL7251096 0.88 HDAC6 (0.56) HDAC6ALDH1A1HSD17B10GAAF2
Hydrochloric Acid SCHEMBL7251214 0.88 HDAC6 (0.56) HDAC6ALDH1A1HSD17B10GAAF2
SCHEMBL7249259 0.87 EPHX2 (0.48) HDAC6ALDH1A1HSD17B10GAAF2
Hydrochloric Acid SCHEMBL7248124 0.86 F2 (0.62) HDAC6ALDH1A1HSD17B10GAAF2
SCHEMBL8029864 0.82 ALDH1A1 (0.49) HDAC6ALDH1A1HSD17B10SMN1; SMN2HDAC1
SCHEMBL6486632 0.82 F2 (0.50) HDAC6ALDH1A1HSD17B10GAAITK
SCHEMBL6775295 0.81 HDAC6 (0.64) HDAC6ITKF2NPC1RAB9A
Hydrochloric Acid SCHEMBL7244675 0.81 F2 (0.49) HDAC6ALDH1A1HSD17B10GAAITK
SCHEMBL6475543 0.79 KDM4E (0.48) HDAC6ITKF2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6512000-B1 Aminocarbonyl- substituted benzimidazole derivatives for the treatment of diseases in which inhibition of tryptase is of therapeutic such as for treating an inflammatory or allergic disease BOEHRINGER INGELHEIM PHARMA KG (DE) 2003-01-28 US disclosed